Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is -38.09% as of the fiscal period ended Wednesday, December 31, 2025.
Limited history available
COAG Return on Invested Capital (ROIC) has fewer than three reported periods, so a trend chart would be misleading.
RETURN ON INVESTED CAPITAL (ROIC)
-38.09%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.64%
median of 838 covered companies
CURRENT VS SECTOR MEDIAN
-6.86%
vs the sector median at left
Hemab Therapeutics Holdings, Inc. Common Stock
Market Cap
$1.33B
Return on Invested Capital (ROIC)
-38.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.34B
Return on Invested Capital (ROIC)
-32.06%
TTM Avg
-61.92%
3Y Avg
-50.73%
5Y Avg
-59.82%
Market Cap
$1.31B
Return on Invested Capital (ROIC)
-40.47%
TTM Avg
-45.26%
3Y Avg
-38.46%
5Y Avg
-34.74%
Market Cap
$1.37B
Return on Invested Capital (ROIC)
-99.35%
TTM Avg
-175.72%
3Y Avg
-121.81%
5Y Avg
-100.94%
Market Cap
$1.39B
Return on Invested Capital (ROIC)
5.22%
TTM Avg
4.86%
3Y Avg
3.97%
5Y Avg
3.44%
Market Cap
$1.40B
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
Return on Invested Capital (ROIC)
-24.52%
TTM Avg
-24.52%
3Y Avg
-24.52%
5Y Avg
-24.52%
Market Cap
$1.40B
Return on Invested Capital (ROIC)
-34.46%
TTM Avg
-51.53%
3Y Avg
-88.71%
5Y Avg
-79.79%
Market Cap
$1.24B
Return on Invested Capital (ROIC)
-40.32%
TTM Avg
-46.81%
3Y Avg
-44.75%
5Y Avg
-38.73%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG) | $1.33B | -38.09% | N/A | N/A | N/A |
| Omeros Corporation (OMER)vs › | $1.34B | -32.06% | -61.92% | -50.73% | -59.82% |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.31B | -40.47% | -45.26% | -38.46% | -34.74% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | -99.35% | -175.72% | -121.81% | -100.94% |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 5.22% | 4.86% | 3.97% | 3.44% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | -24.52% | -24.52% | -24.52% | -24.52% |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | -34.46% | -51.53% | -88.71% | -79.79% |
| ORIC Pharmaceuticals, Inc. (ORIC)vs › | $1.24B | -40.32% | -46.81% | -44.75% | -38.73% |
| Omada Health (OMDA)vs › | $1.23B | -0.18% | -25.12% | -34.79% | -34.79% |
ROIC
-38.1%
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | -38.09% |
